Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID-19 patients.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy Pub Date : 2024-10-01 Epub Date: 2024-05-12 DOI:10.1111/1744-9987.14137

Jan Schmieszek, Thomas Fuehner, Isabelle Renger, Tobias Welte, Jan Menne, Jan Fuge, Maria P Van't Klooster, Andrea Paul, Alina Siegert, Dan-Nicolae Borchina, Christine S Falk, Jan T Kielstein

{"title":"Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID-19 patients.","authors":"Jan Schmieszek, Thomas Fuehner, Isabelle Renger, Tobias Welte, Jan Menne, Jan Fuge, Maria P Van't Klooster, Andrea Paul, Alina Siegert, Dan-Nicolae Borchina, Christine S Falk, Jan T Kielstein","doi":"10.1111/1744-9987.14137","DOIUrl":null,"url":null,"abstract":"Introduction: The Seraph 100 Microbind Affinity blood filter eliminate bacteria, viruses, fungi and toxins from blood stream.Methods: This is a prospective multicenter observational biomarker trial in PCR-positive SARS-CoV-2 patients with acute respiratory failure. Biomarkers were sequentially tested at three time points.Results: Forty-two patients with SARS-CoV-2 detected by PCR with acute respiratory failure were included. When receiving hemoperfusion treatment, 27 (64%) patients were on mechanical ventilation, 41 (98%) patients were treated in the ICU. The 3-month survival was 52%. After one hemoperfusion treatment cycle, D-dimer (p = 0.014), hemoglobin (p = 0.003) and LDH (p = 0.001) concentrations were significantly reduced 4 days after treatment. From the multiplex assay IL-1b, CXCL8/ IL-8, IL-10, IL-13, IL-15, CCL11/Eotaxin, G-CSF, and CXCL10/IP-10 were significantly reduced 1 h after treatment, however not 4 days later.Conclusion: Hemoperfusion with Seraph 100 Microbind Affinity Filter in patients with severe COVID-19 can transiently reduce several inflammatory biomarkers in the blood.","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"802-809"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/1744-9987.14137","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The Seraph 100 Microbind Affinity blood filter eliminate bacteria, viruses, fungi and toxins from blood stream.

Methods: This is a prospective multicenter observational biomarker trial in PCR-positive SARS-CoV-2 patients with acute respiratory failure. Biomarkers were sequentially tested at three time points.

Results: Forty-two patients with SARS-CoV-2 detected by PCR with acute respiratory failure were included. When receiving hemoperfusion treatment, 27 (64%) patients were on mechanical ventilation, 41 (98%) patients were treated in the ICU. The 3-month survival was 52%. After one hemoperfusion treatment cycle, D-dimer (p = 0.014), hemoglobin (p = 0.003) and LDH (p = 0.001) concentrations were significantly reduced 4 days after treatment. From the multiplex assay IL-1b, CXCL8/ IL-8, IL-10, IL-13, IL-15, CCL11/Eotaxin, G-CSF, and CXCL10/IP-10 were significantly reduced 1 h after treatment, however not 4 days later.

Conclusion: Hemoperfusion with Seraph 100 Microbind Affinity Filter in patients with severe COVID-19 can transiently reduce several inflammatory biomarkers in the blood.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

仿生病原体吸附装置对 COVID-19 患者炎症生物标志物的影响。

简介Seraph 100 Microbind Affinity 血液过滤器可清除血液中的细菌、病毒、真菌和毒素：这是一项前瞻性多中心生物标志物观察试验，对象是 PCR 阳性的 SARS-CoV-2 急性呼吸衰竭患者。结果：42 名 SARS-CoV-2 患者的血液中检测到了生物标志物：结果：纳入了 42 名通过 PCR 检测出 SARS-CoV-2 并伴有急性呼吸衰竭的患者。在接受血液灌流治疗时，27 名患者（64%）使用机械通气，41 名患者（98%）在重症监护室接受治疗。3 个月存活率为 52%。一个血液灌流治疗周期后，D-二聚体（p = 0.014）、血红蛋白（p = 0.003）和 LDH（p = 0.001）浓度在治疗后 4 天显著降低。多重检测结果显示，IL-1b、CXCL8/ IL-8、IL-10、IL-13、IL-15、CCL11/Eotaxin、G-CSF 和 CXCL10/IP-10 在治疗 1 小时后明显减少，但 4 天后则没有减少：结论：使用 Seraph 100 微粘附亲和过滤器对重症 COVID-19 患者进行血液灌流可短暂降低血液中的几种炎症生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

自引率

0.00%

发文量